

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email gram.formularyteam@nhs.scot.

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](https://www.FreeDigitalPhotos.net)

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
burosumab 10mg, 20mg, 30mg solution for injection (Crysvita®)	2514	Treatment of X-linked hypophosphataemia in adults.	Not routinely available in NHS Grampian. If local need identified treatment is available through the National Services Scotland Ultra orphan medicines Risk Share Scheme.	18/04/2023
Cacit® D3 500mg/440 IU effervescent granules (calcium/colecalciferol)		<p>- correction of vitamin D and calcium combined deficiency in elderly people</p> <p>- vitamin D and calcium supplementation as an adjunct to specific therapy for osteoporosis treatment in patients with established, or at high risk of vitamin D and calcium combined deficiencies</p> <p>Restriction: for patients requiring administration via enteral feeding tubes.</p>	Routinely available in line with local guidance	18/04/2023
Calcichew®-D3 500mg/200 IU Chewable Tablets (calcium/colecalciferol)		<p>As an adjunct to specific therapy for osteoporosis or as a therapeutic supplement in established osteomalacia, pregnant patients at high risk of needing such a therapeutic supplementation or malnutrition when dietary intake is less than that required.</p> <p>Restriction: for patients requiring administration via enteral feeding tubes.</p>	Routinely available in line with local guidance	18/04/2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Calcichew®-D3 Forte 500mg/400 IU Chewable Tablets (calcium/colecalciferol)		<p>- the treatment and prevention of vitamin D/calcium deficiency (characterised by raised serum alkaline phosphatase levels associated with increased bone loss, raised levels of serum PTH and lowered 25-hydroxyvitamin D) particularly in the housebound and institutionalised elderly subjects</p> <p>- the supplementation of vitamin D and calcium as an adjunct to specific therapy for osteoporosis, in pregnancy, in established vitamin D dependent osteomalacia, and in other situations requiring therapeutic supplementation of malnutrition</p> <p>Restriction: for patients requiring administration via enteral feeding tubes.</p>	Routinely available in line with local guidance	18/04/2023
casirivimab 120mg/mL plus imdevimab 120mg/mL solution for injection or infusion (Ronapreve®)	2553	Treatment of acute COVID-19 infection.	Not routinely available as not recommended for use in NHS Scotland, NICE TA 878 https://www.nice.org.uk/guidance/ta878	18/04/2023
darolutamide 300mg film-coated tablets (Nubeqa®)	2544	Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.	Not routinely available as not recommended for use in NHS Scotland, SMC 2544 https://www.scottishmedicines.org.uk/media/7507/darolutamide-nubeqa-final-march-2023-amended-20032023-for-website.pdf	18/04/2023
diroximel fumarate 231mg gastro-resistant hard capsules (Vumerity®)	2444	Treatment of adult patients with relapsing remitting multiple sclerosis.	Routinely available in line with national guidance, SMC 2444 https://www.scottishmedicines.org.uk/media/6672/diroxime-l-fumarate-vumerity-abbreviated-final-jan-2022-for-website.pdf	18/04/2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
nirmatrelvir 150mg plus ritonavir 100mg film coated tablets (Paxlovid®)	2557	Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19. SMC restriction: patients with increased risk for progression to severe COVID-19, as defined in the independent advisory group report commissioned by the Department of Health.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/04/2023
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	2458	In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5 .	Routinely available in line with national guidance, SMC 2458 https://www.scottishmedicines.org.uk/media/7091/nivolumab-opdivo-final-aug-2022-for-website.pdf	18/04/2023
patiromer sorbitex calcium 8.4g, 16.8g powder for oral suspension (Veltassa®)	2568	Treatment of hyperkalaemia in adults. SMC restriction: in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/04/2023
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2526	As monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/04/2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
sotrovimab 500mg concentrate for solution for infusion (Xevudy®)	2555	Treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection. SMC restriction: patients with increased risk for progression to severe COVID-19, as defined in the independent advisory group report commissioned by the Department of Health and nirmatrelvir and ritonavir is contraindicated or unsuitable.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/04/2023
tocilizumab 20mg/mL concentrate for solution for infusion (RoActemra®)	2552	Treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/04/2023
trastuzumab deruxtecan 100mg powder for concentrate for solution for infusion (Enhertu®)	2545	As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. SMC restriction: in patients who have received one prior anti-HER2-based regimen.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/04/2023
velmanase alfa 10mg powder for solution for infusion (Lamzed®)	2466	Treatment of enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.	Not routinely available in NHS Grampian. If local need identified treatment is available through the National Services Scotland Ultra orphan medicines Risk Share Scheme.	18/04/2023
zanubrutinib 80mg hard capsules (Brukinsa®)	2528	As monotherapy for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.	Routinely available in line with national guidance, SMC 2528 https://www.scottishmedicines.org.uk/media/7211/zanubrutinib-brukinsa-resub-final-oct-2022docxfor-website.pdf	18/04/2023